Glucose-induced gradual phenotypic modulation of cultured human glomerular epithelial cells may be independent of Wilms’ tumor 1 (WT1)

BMC Cell Biology

Garyfalia I Drossopoulou¹  Effie C Tsilibary¹  Eleni S Kotsopoulou¹  Marina Sagnou¹  Nikolaos E Tsotakos¹ 

[1]Institute of Biosciences and Applications, National Centre for Scientific Research “Demokritos”, Athens, Greece

关键词: WT1;    Podocytes;    Dedifferentiation;    Nephrin;    Podocalyxin;   

Others  :  855253
DOI  :  10.1186/1471-2121-14-28

 received in 2012-11-19, accepted in 2013-05-23,  发布年份 2013

【 摘 要 】

Background

Renal podocytes form the main filtration barrier possessing a unique phenotype maintained by proteins including podocalyxin and nephrin, the expression of which is suppressed in pathological conditions. We used an in vitro model of human glomerular epithelial cells (HGEC) to investigate the role of high glucose in dysregulating the podocytic epithelial phenotype and determined the time needed for this change to occur.

Results

In our in vitro podocyte system changes indicating podocyte dedifferentiation in the prolonged presence of high glucose included loss of podocalyxin, nephrin and CD10/CALLA concomitant with upregulation of mesenchymal vimentin. Our study demonstrates for the first time that podocyte-specific markers undergo changes of expression at different time intervals, since glucose-mediated podocalyxin downregulation is a progressive process that precedes downregulation of nephrin expression. Finally we demonstrate that high glucose permanently impaired WT1 binding to the podocalyxin gene promoter region but did not affect WT1 binding on the nephrin gene promoter region.

Conclusion

The presence of high glucose induced a phenotypic conversion of podocytes resembling partial dedifferentiation. Our study demonstrates that dysregulation of the normal podocytic phenotype is an event differentially affecting the expression of function-specific podocytic markers, exhibiting downregulation of the epithelial marker CD10/CALLA and PC first, followed by stably downregulated nephrin. Furthermore, it is herein suggested that WT1 may not be directly involved with upregulation of previously reduced PC and nephrin expression.

【 授权许可】

   
2013 Tsotakos et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Reiser J, Kriz W, Kretzler M, Mundel P: The glomerular slit diaphragm is a modified adherens junction. J Am Soc Nephrol 2000, 11(1):1-8.
• [2]Ronco P: Proteinuria: is it all in the foot? J Clin Invest 2007, 117(8):2079-2082.
• [3]Liu Y: New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010, 21(2):212-222.
• [4]Rhyu DY, Yang Y, Ha H, Lee GT, Song JS, Uh ST, Lee HB: Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol 2005, 16(3):667-675.
• [5]Li Y, Kang YS, Dai C, Kiss LP, Wen X, Liu Y: Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Path 2008, 172(2):299-308.
• [6]Barisoni L, Schnaper HW, Kopp JB: A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2007, 2(3):529-542.
• [7]Herman-Edelstein M, Thomas MC, Thallas-Bonke V, Saleem M, Cooper ME, Kantharidis P: Dedifferentiation of immortalized human podocytes in response to transforming growth factor-beta: a model for diabetic podocytopathy. Diabetes 2011, 60(6):1779-1788.
• [8]Kerjaschki D, Sharkey DJ, Farquhar MG: Identification and characterization of podocalyxin–the major sialoprotein of the renal glomerular epithelial cell. J Cell Biol 1984, 98(4):1591-1596.
• [9]Kershaw DB, Beck SG, Wharram BL, Wiggins JE, Goyal M, Thomas PE, Wiggins RC: Molecular cloning and characterization of human podocalyxin-like protein. Orthologous relationship to rabbit PCLP1 and rat podocalyxin. J Biol Chem 1997, 272(25):15708-15714.
• [10]Tryggvason K: Nephrin: role in normal kidney and in disease. Adv Nephrol Necker Hosp 2001, 31:221-234.
• [11]Economou CG, Kitsiou PV, Tzinia AK, Panagopoulou E, Marinos E, Kershaw DB, Kerjaschki D, Tsilibary EC: Enhanced podocalyxin expression alters the structure of podocyte basal surface. J Cell Sci 2004, 117(Pt 15):3281-3294.
• [12]Drossopoulou GI, Tsotakos NE, Tsilibary EC: Impaired transcription factor interplay in addition to advanced glycation end products suppress podocalyxin expression in high glucose-treated human podocytes. Am J Physiol Renal Physiol 2009, 297(3):F594-F603.
• [13]Benigni A, Gagliardini E, Tomasoni S, Abbate M, Ruggenenti P, Kalluri R, Remuzzi G: Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004, 65(6):2193-2200.
• [14]Miner JH: Focusing on the glomerular slit diaphragm: podocin enters the picture. Am J Path 2002, 160(1):3-5.
• [15]Zhang C, Jiang HJ, Chang Y, Fang Z, Sun XF, Liu JS, Deng AG, Zhu ZH: Downregulation of CD2-associated protein impaired the physiological functions of podocytes. Cell Biol Int 2009, 33(6):632-639.
• [16]Cutrona G, Tasso P, Dono M, Roncella S, Ulivi M, Carpaneto EM, Fontana V, Comis M, Morabito F, Spinelli M, et al.: CD10 is a marker for cycling cells with propensity to apoptosis in childhood ALL. Br J Cancer 2002, 86(11):1776-1785.
• [17]Delarue F, Virone A, Hagege J, Lacave R, Peraldi MN, Adida C, Rondeau E, Feunteun J, Sraer JD: Stable cell line of T-SV40 immortalized human glomerular visceral epithelial cells. Kidney Int 1991, 40(5):906-912.
• [18]Zeisberg M, Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Inv 2009, 119(6):1429-1437.
• [19]Galichon P, Hertig A: Epithelial to mesenchymal transition as a biomarker in renal fibrosis: are we ready for the bedside? Fibrogenesis Tissue Repair 2011, 4:11. BioMed Central Full Text
• [20]Carew RM, Wang B, Kantharidis P: The role of EMT in renal fibrosis. Cell Tissue Res 2012, 347(1):103-116.
• [21]Zou J, Yaoita E, Watanabe Y, Yoshida Y, Nameta M, Li H, Qu Z, Yamamoto T: Upregulation of nestin, vimentin, and desmin in rat podocytes in response to injury. Virchows Arch 2006, 448(4):485-492.
• [22]Zou J, Yaoita E, Watanabe Y, Yoshida Y, Nameta M, Li H, Qu Z, Yamamoto T: Upregulation of nestin, vimentin, and desmin in rat podocytes in response to injury. Virchows Arch 2006, 448(4):485-492.
• [23]Doublier S, Ruotsalainen V, Salvidio G, Lupia E, Biancone L, Conaldi PG, Reponen P, Tryggvason K, Camussi G: Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Path 2001, 158(5):1723-1731.
• [24]Nakagama H, Heinrich G, Pelletier J, Housman DE: Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product. Mol Cellular Biol 1995, 15(3):1489-1498.
• [25]Palmer RE, Kotsianti A, Cadman B, Boyd T, Gerald W, Haber DA: WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin. Curr Biol 2001, 11(22):1805-1809.
• [26]Wagner N, Wagner KD, Xing Y, Scholz H, Schedl A: The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1. J Am Soc Nephrol 2004, 15(12):3044-3051.
• [27]Ziyadeh FN, Wolf G: Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008, 4(1):39-45.
• [28]Li JJ, Kwak SJ, Jung DS, Kim JJ, Yoo TH, Ryu DR, Han SH, Choi HY, Lee JE, Moon SJ, et al.: Podocyte biology in diabetic nephropathy. Kidney Int Suppl 2007, 106:S36-42.
• [29]Shankland SJ: The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006, 69(12):2131-2147.
• [30]Fan JM, Huang XR, Ng YY, Nikolic-Paterson DJ, Mu W, Atkins RC, Lan HY: Interleukin-1 induces tubular epithelial-myofibroblast transdifferentiation through a transforming growth factor-beta1-dependent mechanism in vitro. Am J Kidney Dis 2001, 37(4):820-831.
• [31]Lan HY: Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 2003, 12(1):25-29.
• [32]Zhao L, Yaoita E, Nameta M, Zhang Y, Cuellar LM, Fujinaka H, Xu B, Yoshida Y, Hatakeyama K, Yamamoto T: Claudin-6 localized in tight junctions of rat podocytes. Am J Physiol Regul Integr Comp Physiol 2008, 294(6):R1856-1862.
• [33]Chen S, Lee JS, Iglesias-de la Cruz MC, Wang A, Izquierdo-Lahuerta A, Gandhi NK, Danesh FR, Wolf G, Ziyadeh FN: Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant 2005, 20(7):1320-1328.
• [34]Wu DT, Bitzer M, Ju W, Mundel P, Bottinger EP: TGF-beta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J Am Soc Nephrol 2005, 16(11):3211-3221.
• [35]Susztak K, Raff AC, Schiffer M, Bottinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006, 55(1):225-233.
• [36]Benzing T: Signaling at the slit diaphragm. J Am Soc Nephrol 2004, 15(6):1382-1391.
• [37]Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P: A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 2002, 13(3):630-638.
• [38]Meng X, Ezzati P, Wilkins JA: Requirement of podocalyxin in TGF-beta induced epithelial mesenchymal transition. PLoS One 2011, 6(4):e18715.
• [39]Matsusaka T, Xin J, Niwa S, Kobayashi K, Akatsuka A, Hashizume H, Wang QC, Pastan I, Fogo AB, Ichikawa I: Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 2005, 16(4):1013-1023.
• [40]Guo JK, Menke AL, Gubler MC, Clarke AR, Harrison D, Hammes A, Hastie ND, Schedl A: WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet 2002, 11(6):651-659.
• [41]Butta N, Larrucea S, Alonso S, Rodriguez RB, Arias-Salgado EG, Ayuso MS, Gonzalez-Manchon C, Parrilla R: Role of transcription factor Sp1 and CpG methylation on the regulation of the human podocalyxin gene promoter. BMC Mol Biol 2006, 7:17. BioMed Central Full Text
• [42]Beltcheva O, Hjorleifsdottir EE, Kontusaari S, Tryggvason K: Sp1 specifically binds to an evolutionarily conserved DNA segment within a region necessary for podocyte-specific expression of nephrin. Nephron Exp Nephrol 2010, 114(1):e15-22.
• [43]Deb DK, Wang Y, Zhang Z, Nie H, Huang X, Yuan Z, Chen Y, Zhao Q, Li YC: Molecular mechanism underlying 1,25-dihydroxyvitamin D regulation of nephrin gene expression. J Biol Chem 2011, 286(37):32011-32017.
• [44]Kitsiou PV, Tzinia AK, Stetler-Stevenson WG, Michael AF, Fan WW, Zhou B, Tsilibary EC: Glucose-induced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells. Am J Physiol Renal Physiol 2003, 284(4):F671-679.
• [45]Collino F, Bussolati B, Gerbaudo E, Marozio L, Pelissetto S, Benedetto C, Camussi G: Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol 2008, 294(5):F1185-1194.
• [46]Chakrabarti SK, James JC, Mirmira RG: Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1 Importance of chromatin structure in directing promoter binding. J Biol Chem 2002, 277(15):13286-13293.